Clinical trials: Nonadherence, Patient
Colorectal Cancer
Adherence to Minimally Invasive Testing
Colorectal cancer (CRC) screening has been demonstrated to reduce long term disease burden and costs. Unfortunately, less than 65 % of age-eligible persons in the US are actually screened for CRC.
- Trial name
- ADMIT (NCT02251782)
- Testing
- Epi proColon Test, Fecal Immunochemical Test (FIT)
- Where
- 2 sites in United States
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Epigenomics, Inc
Bipolar Disorder, Schizophrenia
Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study
Feasibility study of using a digital health feedback system (DHFS) to monitor medication-taking and physiologic and behavioral parameters in patients with bipolar disorder or schizophrenia.
- Trial name
- EMITTER3PSY (NCT01804257)
- Testing
- Digital Health Feedback System
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Proteus Digital Health, Inc.
Opiate Addiction, Medication Non-adherence
Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy
This study uses an artificial intelligence platform to automatically confirm medication ingestion. The Health Insurance Portability and Accountability Act (HIPAA)-compliant platform can be downloaded as an 'app' onto any…
- Conditions
- Opiate Addiction, Medication Non-adherence, Addiction, Opioid Dependence
- Trial name
- NCT02243670
- Testing
- AiCure monitoring and intervention
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- AiCure
Stroke
Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.
AiCure uses artificial intelligence and visual recognition technology to confirm medication ingestion. The software is available as an app and downloaded onto a smart phone.
- Trial name
- NCT02599259
- Testing
- Monitored (M+)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- AiCure
Hepatitis C, Chronic, Nonadherence, Patient
Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence
This study evaluates the ability of digital medicines, Proteus Discover, to promote adherence and thus achieving a cure for hepatitis C in patients at high risk for not adhering to their hepatitis therapy.
- Trial name
- DASH (NCT03164902)
- Testing
- Digital Medicine
- Where
- 16 sites in United States
- Volunteers
- 253 people
- Sponsor
- Proteus Digital Health, Inc.